Bio-Techne (TECH) Financials

$51.12 -0.42 (-0.81%)

As of 10:05 AM Eastern

Annual Income Statements for Bio-Techne

This table shows Bio-Techne's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	6/30/2015	6/30/2016	6/30/2017	6/30/2018	6/30/2019	6/30/2020	6/30/2021	6/30/2022	6/30/2023	6/30/2024
Net Income / (Loss) Attributable to Common Shareholders	108	104	76	126	96	229	140	272	285	168
Consolidated Net Income / (Loss)	108	104	76	126	96	229	140	263	285	168
Net Income / (Loss) Continuing Operations	108	104	76	126	96	229	140	263	285	168
Total Pre-Tax Income	154	147	112	126	112	276	148	301	339	186
Total Operating Income	147	151	121	136	147	157	237	297	299	207
Total Gross Profit	307	337	375	432	473	483	633	756	770	770
Total Revenue	452	499	563	643	714	739	931	1,106	1,137	1,159
Operating Revenue	452	499	563	643	714	739	931	1,106	1,137	1,159
Total Cost of Revenue	145	162	188	211	241	255	298	349	367	389
Operating Cost of Revenue	145	162	188	211	241	255	298	349	367	389
Total Operating Expenses	160	186	254	296	327	326	396	460	471	563
Selling, General & Admin Expense	119	141	200	241	264	261	325	373	378	466
Research & Development Expense	41	45	54	55	62	65	71	87	92	97
Total Other Income / (Expense), net	7.14	-3.11	-8.62	-10	-35	119	-89	4.80	40	-21
Interest Expense	1.54	1.75	7.36	10	22	19	14	11	11	16
Interest & Investment Income	0.63	0.25	0.30	0.41	0.57	0.61	0.47	0.79	3.41	3.32
Other Income / (Expense), net	8.05	-1.61	-1.57	-0.45	-14	138	-76	15	48	-8.58
Income Tax Expense	46	43	36	-0.20	16	47	8.59	38	53	18
Net Income / (Loss) Attributable to Noncontrolling Interest	-	-	-	-	0.00	0.00	-0.83	-8.95	0.18	0.00
Basic Earnings per Share	$2.90	$2.81	$2.04	$3.36	$2.54	$6.00	$0.91	$1.73	$1.81	$1.07
Weighted Average Basic Shares Outstanding	37.10M	37.19M	37.31M	37.48M	37.78M	38.20M	154.99M	156.87M	157.18M	157.71M
Diluted Earnings per Share	$2.89	$2.80	$2.03	$3.31	$2.47	$5.82	$0.87	$1.66	$1.76	$1.05
Weighted Average Diluted Shares Outstanding	37.23M	37.33M	37.50M	38.06M	38.89M	39.40M	161.93M	164.11M	161.86M	160.77M
Weighted Average Basic & Diluted Shares Outstanding	37.20M	37.20M	37.30M	37.50M	37.80M	38.55M	39.08M	39.21M	158.17M	158.60M
Cash Dividends to Common per Share	$1.27	$1.28	$1.28	$1.28	$1.28	$1.28	$1.28	$1.28	$0.32	$0.32

This table shows Bio-Techne's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025
Net Income / (Loss) Attributable to Common Shareholders	90	50	70	75	51	27	49	41	34	35	23
Consolidated Net Income / (Loss)	90	50	70	75	51	27	49	41	34	35	23
Net Income / (Loss) Continuing Operations	90	50	70	75	51	27	49	41	34	35	23
Total Pre-Tax Income	104	66	80	88	50	33	61	42	40	43	38
Total Operating Income	56	68	80	95	56	38	67	46	40	47	39
Total Gross Profit	180	183	202	205	185	177	205	203	183	194	215
Total Revenue	270	272	294	301	277	273	303	306	289	297	316
Operating Revenue	270	272	294	301	277	273	303	306	289	297	316
Total Cost of Revenue	90	88	92	97	92	96	99	103	106	103	102
Operating Cost of Revenue	90	88	92	97	92	96	99	103	106	103	102
Total Operating Expenses	123	115	122	110	129	139	138	158	143	146	176
Selling, General & Admin Expense	99	93	99	87	105	116	112	134	119	121	151
Research & Development Expense	24	22	23	23	24	23	26	24	24	25	25
Total Other Income / (Expense), net	47	-1.46	-0.02	-6.21	-6.30	-4.62	-5.91	-4.16	0.18	-4.54	-0.43
Income Tax Expense	14	16	9.98	13	-1.44	5.92	12	1.07	6.57	7.99	16
Basic Earnings per Share	$0.57	$0.32	$0.45	$0.48	$0.32	$0.17	$0.31	$0.26	$0.21	$0.22	$0.14
Weighted Average Basic Shares Outstanding	156.93M	157.01M	157.31M	157.18M	158.13M	157.53M	157.31M	157.71M	158.53M	158.43M	157.37M
Diluted Earnings per Share	$0.55	$0.31	$0.43	$0.48	$0.31	$0.17	$0.31	$0.26	$0.21	$0.22	$0.14
Weighted Average Diluted Shares Outstanding	162.17M	161.75M	161.62M	161.86M	161.94M	160.06M	160.50M	160.77M	161.12M	160.63M	158.94M
Weighted Average Basic & Diluted Shares Outstanding	39.24M	157.28M	157.44M	158.17M	158.15M	157.19M	157.58M	158.60M	158.89M	158.09M	156.77M
Cash Dividends to Common per Share	$0.32	$0.08	$0.08	$0.08	$0.08	$0.08	$0.08	$0.08	$0.08	$0.08	$0.08

This table details how cash moves in and out of Bio-Techne's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	6/30/2015	6/30/2016	6/30/2017	6/30/2018	6/30/2019	6/30/2020	6/30/2021	6/30/2022	6/30/2023	6/30/2024
Net Change in Cash & Equivalents	-264	9.71	27	32	-21	46	52	-27	8.00	-29
Net Cash From Operating Activities	139	144	144	170	182	205	352	325	254	299
Net Cash From Continuing Operating Activities	139	144	144	170	182	205	352	325	254	299
Net Income / (Loss) Continuing Operations	108	104	76	126	96	229	140	263	285	168
Consolidated Net Income / (Loss)	108	104	76	126	96	229	140	263	285	168
Depreciation Expense	37	43	60	64	78	83	88	101	107	112
Non-Cash Adjustments To Reconcile Net Income	4.46	15	36	50	46	-113	124	26	-19	68
Changes in Operating Assets and Liabilities, net	-10	-18	-28	-71	-39	6.19	1.03	-65	-120	-49
Net Cash From Investing Activities	-426	-108	-306	-39	-337	27	-244	-97	-266	-203
Net Cash From Continuing Investing Activities	-426	-108	-306	-39	-337	27	-244	-97	-266	-203
Purchase of Property, Plant & Equipment	-20	-17	-15	-21	-25	-52	-44	-45	-38	-63
Acquisitions	-420	-91	-254	-68	-289	0.00	-225	0.00	-101	-170
Purchase of Investments	0.00	0.00	-43	-8.57	-43	-68	-40	-78	-21	-5.53
Divestitures	-	-	-	-	-	-	0.00	0.00	18	0.00
Sale and/or Maturity of Investments	13	0.78	6.08	58	22	147	66	26	108	28
Other Investing Activities, net	0.05	-0.03	0.00	0.68	0.00	-	-	0.00	-232	7.00
Net Cash From Financing Activities	31	-23	189	-99	134	-184	-63	-243	23	-122
Net Cash From Continuing Financing Activities	31	-23	189	-99	134	-184	-63	-243	23	-122
Repayment of Debt	-95	-59	-118	-63	-420	-189	-272	-175	-528	-256
Repurchase of Common Equity	-	-	0.00	0.00	-15	-50	-43	-161	-20	-80
Payment of Dividends	-47	-48	-47	-48	-48	-49	-50	-50	-50	-50
Issuance of Debt	163	77	369	55	580	40	256	90	620	225
Other Financing Activities, net	10	6.02	-15	-43	38	64	46	53	0.92	39
Effect of Exchange Rate Changes	-8.18	-3.51	0.50	-	-0.31	-	6.37	-12	-3.36	-2.33
Cash Interest Paid	-	-	-	-	-	-	-	11	8.37	15

This table details how cash moves in and out of Bio-Techne's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025
Net Change in Cash & Equivalents	-7.31	-0.58	-37	53	-32	-19	9.78	12	36	-9.99	-37
Net Cash From Operating Activities	56	64	51	83	59	83	81	75	64	84	41
Net Cash From Continuing Operating Activities	56	64	51	83	59	83	81	75	64	84	41
Net Income / (Loss) Continuing Operations	90	50	70	75	51	27	49	41	34	35	23
Consolidated Net Income / (Loss)	90	50	70	75	51	27	49	41	34	35	23
Depreciation Expense	27	27	27	27	29	28	27	28	28	27	28
Non-Cash Adjustments To Reconcile Net Income	-33	6.51	8.84	-1.39	11	20	11	26	17	18	8.64
Changes in Operating Assets and Liabilities, net	-28	-19	-55	-18	-31	8.13	-6.09	-20	-14	3.68	-18
Net Cash From Investing Activities	-20	-0.11	-241	-4.76	-154	-24	-16	-8.81	-22	-5.03	-8.87
Net Cash From Continuing Investing Activities	-20	-0.11	-241	-4.76	-154	-24	-16	-8.81	-22	-5.03	-8.87
Purchase of Property, Plant & Equipment	-9.56	-6.11	-12	-11	-14	-15	-16	-18	-9.17	-6.82	-10
Sale and/or Maturity of Investments	88	12	2.65	6.08	26	-	-	2.18	2.49	-	1.25
Net Cash From Financing Activities	-32	-72	151	-24	72	-81	-52	-60	-12	-84	-68
Net Cash From Continuing Financing Activities	-32	-72	151	-24	72	-81	-52	-60	-12	-84	-68
Repayment of Debt	-443	-65	-	-20	-70	-58	-58	-70	-19	-	-8.00
Repurchase of Common Equity	-20	-	-	-	-	-	-	-	-	-	-100
Payment of Dividends	-13	-13	-13	-13	-13	-13	-13	-13	-13	-13	-13
Issuance of Debt	450	-	170	-	160	65	-	-	0.00	-	38
Other Financing Activities, net	-5.90	5.03	-6.58	8.38	-5.83	4.20	18	23	20	4.53	15
Effect of Exchange Rate Changes	-12	7.35	2.32	-1.13	-8.69	3.42	-2.35	5.28	5.12	-5.47	-1.08
Cash Interest Paid	3.41	2.21	0.15	2.60	4.51	4.08	3.81	2.11	5.21	4.63	4.40
Cash Income Taxes Paid	15	12	36	-	33	4.85	7.20	-	16	21	18

This table presents Bio-Techne's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	6/30/2015	6/30/2016	6/30/2017	6/30/2018	6/30/2019	6/30/2020	6/30/2021	6/30/2022	6/30/2023	6/30/2024
Total Assets	1,063	1,130	1,558	1,593	1,884	2,028	2,263	2,295	2,639	2,704
Total Current Assets	248	254	348	398	413	521	511	606	621	617
Cash & Equivalents	55	64	92	122	101	147	199	173	181	152
Short-Term Investments	56	32	66	60	65	124	32	74	24	1.07
Accounts Receivable	70	93	117	120	137	123	145	195	218	241
Inventories, net	50	57	60	86	91	103	117	141	172	180
Other Current Assets	6.24	7.56	13	11	18	24	17	23	27	34
Other Current Nonoperating Assets	-	-	-	-	-	-	-	-	0.00	9.77
Plant, Property, & Equipment, net	130	132	135	145	154	177	208	223	226	251
Total Noncurrent Assets	685	743	1,075	1,049	1,318	1,330	1,544	1,466	1,791	1,835
Goodwill	391	431	579	598	733	728	843	822	873	973
Intangible Assets	293	311	452	446	579	517	616	532	535	507
Other Noncurrent Operating Assets	1.85	1.92	44	5.27	5.67	85	85	112	384	356
Total Liabilities & Shareholders' Equity	1,063	1,130	1,558	1,593	1,884	2,028	2,263	2,295	2,639	2,704
Total Liabilities	216	250	609	514	719	646	692	589	672	635
Total Current Liabilities	40	54	136	80	102	107	152	176	129	159
Accounts Payable	13	21	17	18	16	23	29	34	26	38
Accrued Expenses	6.60	8.37	19	20	26	9.09	15	18	15	25
Current Deferred Revenue	3.38	4.72	5.97	-	9.08	-	-	23	23	28
Current Deferred & Payable Income Tax Liabilities	1.97	1.78	2.48	8.88	5.76	2.38	5.34	13	12	3.71
Current Employee Benefit Liabilities	10	15	27	24	29	31	51	62	37	50
Other Current Liabilities	-	-	-	8.11	0.00	23	34	13	13	15
Total Noncurrent Liabilities	177	196	473	435	617	540	539	413	544	476
Long-Term Debt	73	92	344	339	493	344	329	243	350	319
Noncurrent Deferred & Payable Income Tax Liabilities	61	63	121	86	90	101	93	99	89	56
Other Noncurrent Operating Liabilities	42	42	8.70	9.34	34	94	117	70	105	101
Total Equity & Noncontrolling Interests	847	879	950	1,079	1,166	1,381	1,571	1,701	1,967	2,069
Total Preferred & Common Equity	847	879	950	1,079	1,166	1,381	1,563	1,702	1,967	2,069
Total Common Equity	847	879	950	1,079	1,166	1,381	1,563	1,702	1,967	2,069
Common Stock	164	179	200	247	317	421	535	654	723	822
Retained Earnings	714	771	799	877	932	1,057	1,085	1,123	1,309	1,325
Accumulated Other Comprehensive Income / (Loss)	-31	-70	-49	-45	-84	-97	-57	-75	-66	-78

This table presents Bio-Techne's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025
Total Assets	2,351	2,363	2,600	2,639	2,755	2,731	2,721	2,704	2,736	2,670	2,644
Total Current Assets	552	565	571	621	591	591	611	617	649	635	627
Cash & Equivalents	165	165	127	181	149	130	140	152	188	178	141
Short-Term Investments	38	32	30	24	0.00	5.52	5.40	1.07	0.00	0.00	0.00
Accounts Receivable	174	185	216	218	205	207	228	241	224	218	237
Inventories, net	150	160	169	172	186	181	179	180	185	188	191
Other Current Assets	25	23	28	27	52	40	31	34	43	50	54
Other Current Nonoperating Assets	-	-	-	0.00	-	27	27	9.77	9.46	1.05	4.70
Plant, Property, & Equipment, net	224	224	224	226	232	234	244	251	254	250	252
Total Noncurrent Assets	1,575	1,574	1,805	1,791	1,932	1,906	1,867	1,835	1,834	1,786	1,765
Goodwill	865	870	871	873	969	980	971	973	983	965	969
Intangible Assets	586	568	553	535	579	551	526	507	486	461	444
Other Noncurrent Operating Assets	124	137	381	384	384	375	369	356	365	360	353
Total Liabilities & Shareholders' Equity	2,351	2,363	2,600	2,639	2,755	2,731	2,721	2,704	2,736	2,670	2,644
Total Liabilities	600	536	710	672	758	767	707	635	597	592	626
Total Current Liabilities	138	128	141	129	128	135	150	159	142	161	169
Accounts Payable	30	24	27	26	28	32	29	38	32	33	32
Accrued Expenses	14	16	16	15	16	17	18	25	21	28	24
Current Deferred Revenue	-	-	25	23	25	28	30	28	27	28	32
Current Deferred & Payable Income Tax Liabilities	17	25	18	12	5.94	6.65	12	3.71	3.14	3.14	3.63
Current Employee Benefit Liabilities	33	29	39	37	35	33	44	50	42	54	62
Other Current Liabilities	36	34	12	13	17	17	16	15	18	16	16
Total Noncurrent Liabilities	462	408	569	544	630	632	557	476	455	431	457
Long-Term Debt	265	200	370	350	440	447	389	319	300	300	330
Noncurrent Deferred & Payable Income Tax Liabilities	113	111	95	89	83	72	64	56	50	38	32
Other Noncurrent Operating Liabilities	84	97	104	105	107	113	104	101	105	93	95
Total Equity & Noncontrolling Interests	1,751	1,827	1,890	1,967	1,998	1,964	2,014	2,069	2,139	2,078	2,018
Total Preferred & Common Equity	1,751	1,827	1,890	1,967	1,998	1,964	2,014	2,069	2,139	2,078	2,018
Total Common Equity	1,751	1,827	1,890	1,967	1,998	1,964	2,014	2,069	2,139	2,078	2,018
Common Stock	680	702	717	723	748	766	792	822	858	877	904
Retained Earnings	1,163	1,200	1,247	1,309	1,328	1,261	1,298	1,325	1,341	1,287	1,196
Accumulated Other Comprehensive Income / (Loss)	-92	-75	-74	-66	-78	-64	-75	-78	-60	-86	-82

This table displays calculated financial ratios and metrics derived from Bio-Techne's official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	6/30/2015	6/30/2016	6/30/2017	6/30/2018	6/30/2019	6/30/2020	6/30/2021	6/30/2022	6/30/2023	6/30/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	26.41%	10.34%	12.82%	14.21%	11.04%	3.46%	26.04%	18.75%	2.81%	1.97%
EBITDA Growth	8.10%	-0.29%	-6.62%	11.81%	5.56%	78.78%	-33.99%	65.58%	9.86%	-31.71%
EBIT Growth	-2.29%	-3.93%	-20.11%	14.04%	-1.90%	121.60%	-45.21%	92.94%	11.08%	-42.82%
NOPAT Growth	-6.44%	3.83%	-23.19%	66.44%	-7.74%	3.75%	71.22%	15.82%	-2.68%	-25.74%
Net Income Growth	-2.90%	-3.03%	-27.17%	65.80%	-23.84%	138.67%	-39.12%	88.49%	8.49%	-41.11%
EPS Growth	-3.67%	-3.11%	-27.50%	63.05%	-25.38%	135.63%	-39.12%	88.49%	6.02%	-40.34%
Operating Cash Flow Growth	1.90%	3.44%	-0.30%	18.54%	6.60%	12.99%	71.61%	-7.64%	-21.79%	17.53%
Free Cash Flow Firm Growth	-466.62%	114.68%	-685.47%	142.01%	-244.71%	213.51%	-93.05%	1,889.38%	-164.99%	152.14%
Invested Capital Growth	88.71%	8.08%	36.65%	2.96%	21.99%	-2.33%	14.39%	1.77%	23.37%	5.18%
Revenue Q/Q Growth	5.89%	3.55%	4.03%	3.82%	1.62%	-2.10%	9.81%	2.71%	1.17%	0.41%
EBITDA Q/Q Growth	3.54%	0.67%	5.74%	13.33%	-8.39%	10.94%	-14.61%	7.41%	15.99%	-15.34%
EBIT Q/Q Growth	1.56%	0.08%	4.97%	18.46%	-14.25%	13.98%	-22.29%	9.59%	21.57%	-22.43%
NOPAT Q/Q Growth	-0.38%	1.14%	2.63%	-1.82%	3.11%	2.90%	18.45%	-3.28%	7.12%	-16.14%
Net Income Q/Q Growth	-0.46%	-0.67%	2.67%	12.58%	-20.81%	22.68%	-24.05%	21.90%	4.99%	-17.19%
EPS Q/Q Growth	-0.69%	-0.71%	2.53%	11.45%	-21.09%	19.26%	-24.05%	21.90%	2.33%	-18.60%
Operating Cash Flow Q/Q Growth	-0.56%	-0.34%	10.96%	8.95%	-4.67%	-5.16%	28.09%	-5.60%	-7.06%	-2.57%
Free Cash Flow Firm Q/Q Growth	8.80%	-95.14%	77.41%	24.74%	-56.55%	1.13%	-92.46%	1,122.05%	-13.32%	-21.44%
Invested Capital Q/Q Growth	-0.26%	1,040.74%	-1.56%	-3.25%	1.00%	1.15%	12.92%	-1.51%	0.38%	-0.31%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	67.94%	67.46%	66.53%	67.21%	66.31%	65.41%	67.97%	68.42%	67.72%	66.41%
EBITDA Margin	42.52%	38.42%	31.80%	31.13%	29.60%	51.15%	26.79%	37.35%	39.91%	26.73%
Operating Margin	32.51%	30.18%	21.42%	21.18%	20.55%	21.31%	25.49%	26.83%	26.30%	17.83%
EBIT Margin	34.29%	29.85%	21.14%	21.11%	18.65%	39.94%	17.36%	28.21%	30.48%	17.09%
Profit (Net Income) Margin	23.82%	20.94%	13.51%	19.62%	13.46%	31.04%	14.99%	23.80%	25.11%	14.50%
Tax Burden Percent	69.88%	70.84%	67.96%	100.16%	85.77%	82.93%	94.20%	87.30%	84.29%	90.53%
Interest Burden Percent	99.41%	98.99%	94.07%	92.80%	84.13%	93.70%	91.66%	96.63%	97.75%	93.73%
Effective Tax Rate	30.12%	29.16%	32.04%	-0.16%	14.23%	17.07%	5.80%	12.70%	15.71%	9.47%
Return on Invested Capital (ROIC)	16.52%	12.61%	7.88%	11.19%	9.17%	8.76%	14.16%	15.23%	13.16%	8.62%
ROIC Less NNEP Spread (ROIC-NNEP)	14.02%	25.40%	3.20%	6.18%	-2.74%	54.23%	-67.53%	21.79%	54.21%	-3.82%
Return on Net Nonoperating Assets (RNNOA)	-3.40%	-0.51%	0.44%	1.24%	-0.61%	9.25%	-4.70%	0.85%	2.41%	-0.29%
Return on Equity (ROE)	13.12%	12.10%	8.32%	12.44%	8.56%	18.01%	9.46%	16.08%	15.57%	8.33%
Cash Return on Invested Capital (CROIC)	-44.93%	4.85%	-23.10%	8.28%	-10.64%	11.12%	0.73%	13.47%	-7.77%	3.58%
Operating Return on Assets (OROA)	16.10%	13.59%	8.86%	8.61%	7.66%	15.09%	7.54%	13.69%	14.05%	7.42%
Return on Assets (ROA)	11.19%	9.53%	5.66%	8.01%	5.53%	11.72%	6.51%	11.55%	11.57%	6.29%
Return on Common Equity (ROCE)	13.12%	12.10%	8.32%	12.44%	8.56%	18.01%	9.43%	16.04%	15.57%	8.33%
Return on Equity Simple (ROE_SIMPLE)	12.72%	11.88%	8.01%	11.69%	8.24%	16.60%	8.93%	15.46%	14.52%	8.13%
Net Operating Profit after Tax (NOPAT)	103	107	82	136	126	131	224	259	252	187
NOPAT Margin	22.72%	21.38%	14.56%	21.21%	17.62%	17.67%	24.01%	23.42%	22.17%	16.14%
Net Nonoperating Expense Percent (NNEP)	2.51%	-12.79%	4.68%	5.02%	11.91%	-45.47%	81.68%	-6.56%	-41.05%	12.44%
Cost of Revenue to Revenue	32.06%	32.54%	33.47%	32.79%	33.69%	34.59%	32.03%	31.58%	32.28%	33.59%
SG&A Expenses to Revenue	26.40%	28.23%	35.60%	37.42%	37.02%	35.28%	34.90%	33.72%	33.29%	40.24%
R&D to Revenue	9.03%	9.06%	9.51%	8.60%	8.74%	8.83%	7.58%	7.88%	8.14%	8.34%
Operating Expenses to Revenue	35.44%	37.29%	45.11%	46.03%	45.77%	44.10%	42.49%	41.60%	41.42%	48.58%
Earnings before Interest and Taxes (EBIT)	155	149	119	136	133	295	162	312	346	198
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	192	192	179	200	211	378	249	413	454	310
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	4.05	4.53	4.44	5.00	6.60	7.18	11.05	7.91	6.50	5.45
Price to Tangible Book Value (P/TBV)	20.96	28.89	0.00	154.81	0.00	72.76	166.23	38.66	22.86	19.15
Price to Revenue (P/Rev)	7.58	7.98	7.49	8.39	10.77	13.43	18.56	12.17	11.24	9.73
Price to Earnings (P/E)	31.80	38.13	55.40	42.76	80.06	43.26	123.05	49.47	44.80	67.09
Dividend Yield	1.38%	1.20%	1.13%	0.89%	0.63%	0.49%	0.29%	0.37%	0.49%	0.45%
Earnings Yield	3.14%	2.62%	1.81%	2.34%	1.25%	2.31%	0.81%	2.02%	2.23%	1.49%
Enterprise Value to Invested Capital (EV/IC)	4.17	4.53	3.72	4.49	5.33	6.80	10.33	7.85	6.11	5.14
Enterprise Value to Revenue (EV/Rev)	7.50	7.98	7.93	8.63	11.25	13.55	18.69	12.18	11.37	9.87
Enterprise Value to EBITDA (EV/EBITDA)	17.64	20.77	24.94	27.73	38.02	26.50	69.76	32.61	28.50	36.94
Enterprise Value to EBIT (EV/EBIT)	21.87	26.74	37.53	40.90	60.34	33.93	107.63	43.18	37.32	57.77
Enterprise Value to NOPAT (EV/NOPAT)	33.02	37.34	54.50	40.70	63.85	76.68	77.84	52.01	51.31	61.17
Enterprise Value to Operating Cash Flow (EV/OCF)	24.34	27.63	31.08	32.58	44.24	48.79	49.41	41.40	50.82	38.28
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	97.11	0.00	55.03	0.00	60.42	1,511.35	58.80	0.00	147.48
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.09	0.11	0.43	0.31	0.44	0.26	0.22	0.15	0.18	0.15
Long-Term Debt to Equity	0.09	0.10	0.36	0.31	0.42	0.25	0.21	0.14	0.18	0.15
Financial Leverage	-0.24	-0.02	0.14	0.20	0.22	0.17	0.07	0.04	0.04	0.08
Leverage Ratio	1.17	1.27	1.47	1.55	1.55	1.54	1.45	1.39	1.35	1.32
Compound Leverage Factor	1.17	1.26	1.38	1.44	1.30	1.44	1.33	1.35	1.31	1.24
Debt to Total Capital	8.34%	9.77%	30.10%	23.91%	30.38%	20.80%	18.02%	13.08%	15.24%	13.36%
Short-Term Debt to Total Capital	0.44%	0.39%	4.79%	0.00%	0.95%	1.06%	0.86%	0.64%	0.15%	0.00%
Long-Term Debt to Total Capital	7.90%	9.39%	25.31%	23.91%	29.43%	19.74%	17.16%	12.44%	15.09%	13.36%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.43%	-0.04%	0.00%	0.00%
Common Equity to Total Capital	91.66%	90.23%	69.90%	76.09%	69.62%	79.20%	81.55%	86.96%	84.76%	86.64%
Debt to EBITDA	0.40	0.50	2.28	1.69	2.41	0.96	1.38	0.62	0.78	1.03
Net Debt to EBITDA	-0.18	0.00	1.40	0.79	1.62	0.24	0.46	0.02	0.33	0.54
Long-Term Debt to EBITDA	0.38	0.48	1.92	1.69	2.33	0.91	1.32	0.59	0.77	1.03
Debt to NOPAT	0.75	0.89	4.99	2.49	4.04	2.78	1.54	0.99	1.40	1.70
Net Debt to NOPAT	-0.33	-0.01	3.06	1.15	2.72	0.70	0.51	0.03	0.59	0.89
Long-Term Debt to NOPAT	0.71	0.86	4.20	2.49	3.92	2.64	1.47	0.94	1.39	1.70
Altman Z-Score	11.58	11.59	5.65	7.99	7.92	11.03	16.50	15.55	13.19	12.22
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.28%	0.23%	-0.02%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	6.24	4.69	2.57	5.01	4.05	4.88	3.35	3.44	4.84	3.87
Quick Ratio	4.55	3.49	2.03	3.80	2.98	3.69	2.48	2.51	3.29	2.47
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-279	41	-240	101	-146	166	12	229	-149	78
Operating Cash Flow to CapEx	700.12%	853.10%	946.84%	813.83%	714.73%	396.60%	794.93%	724.31%	665.18%	475.50%
Free Cash Flow to Firm to Interest Expense	-181.00	23.46	-32.62	9.90	-6.73	8.63	0.83	20.25	-13.27	4.93
Operating Cash Flow to Interest Expense	90.26	82.47	19.52	16.72	8.37	10.69	25.24	28.76	22.68	19.00
Operating Cash Flow Less CapEx to Interest Expense	77.37	72.80	17.46	14.67	7.20	7.99	22.07	24.79	19.27	15.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.47	0.46	0.42	0.41	0.41	0.38	0.43	0.49	0.46	0.43
Accounts Receivable Turnover	7.23	6.11	5.36	5.42	5.54	5.68	6.95	6.50	5.50	5.04
Inventory Turnover	3.28	3.04	3.21	2.89	2.72	2.63	2.71	2.71	2.35	2.22
Fixed Asset Turnover	3.66	3.81	4.21	4.59	4.77	4.47	4.84	5.13	5.06	4.86
Accounts Payable Turnover	12.55	9.52	10.05	11.94	13.88	13.00	11.36	11.04	12.32	12.23
Days Sales Outstanding (DSO)	50.46	59.77	68.14	67.30	65.88	64.24	52.52	56.11	66.31	72.41
Days Inventory Outstanding (DIO)	111.32	119.91	113.54	126.20	134.08	138.72	134.59	134.81	155.58	164.70
Days Payable Outstanding (DPO)	29.07	38.32	36.32	30.56	26.30	28.07	32.12	33.06	29.62	29.83
Cash Conversion Cycle (CCC)	132.70	141.35	145.37	162.94	173.66	174.88	154.99	157.85	192.27	207.28
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	813	879	1,201	1,236	1,508	1,473	1,685	1,715	2,116	2,225
Invested Capital Turnover	0.73	0.59	0.54	0.53	0.52	0.50	0.59	0.65	0.59	0.53
Increase / (Decrease) in Invested Capital	382	66	322	36	272	-35	212	30	401	110
Enterprise Value (EV)	3,392	3,983	4,466	5,551	8,034	10,012	17,399	13,467	12,929	11,445
Market Capitalization	3,426	3,984	4,215	5,394	7,692	9,920	17,277	13,458	12,780	11,279
Book Value per Share	$22.80	$23.63	$25.44	$28.72	$30.86	$36.14	$40.19	$43.38	$12.49	$13.13
Tangible Book Value per Share	$4.40	$3.70	($2.18)	$0.93	($3.88)	$3.57	$2.67	$8.87	$3.55	$3.74
Total Capital	924	975	1,358	1,418	1,674	1,744	1,917	1,957	2,320	2,388
Total Debt	77	95	409	339	509	363	345	256	354	319
Total Long-Term Debt	73	92	344	339	493	344	329	243	350	319
Net Debt	-34	-0.58	251	157	343	92	114	8.88	149	166
Capital Expenditures (CapEx)	20	17	15	21	25	52	44	45	38	63
Debt-free, Cash-free Net Working Capital (DFCFNWC)	102	108	120	137	160	162	143	195	292	305
Debt-free Net Working Capital (DFNWC)	213	204	278	319	327	433	375	442	496	458
Net Working Capital (NWC)	209	200	213	319	311	414	358	430	493	458
Net Nonoperating Expense (NNE)	-4.99	2.20	5.86	10	30	-99	84	-4.19	-33	19
Net Nonoperating Obligations (NNO)	-34	-0.58	251	157	343	92	114	14	149	156
Total Depreciation and Amortization (D&A)	37	43	60	64	78	83	88	101	107	112
Debt-free, Cash-free Net Working Capital to Revenue	22.47%	21.58%	21.29%	21.32%	22.48%	21.90%	15.39%	17.64%	25.70%	26.33%
Debt-free Net Working Capital to Revenue	47.00%	40.78%	49.31%	49.59%	45.73%	58.58%	40.26%	39.98%	43.68%	39.52%
Net Working Capital to Revenue	46.11%	40.03%	37.74%	49.59%	43.50%	56.08%	38.49%	38.85%	43.37%	39.52%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.73	$0.70	$0.51	$0.84	$0.64	$1.50	$0.91	$1.73	$1.81	$1.07
Adjusted Weighted Average Basic Shares Outstanding	148.38M	148.78M	149.25M	149.90M	151.12M	152.80M	154.99M	156.88M	157.18M	157.71M
Adjusted Diluted Earnings per Share	$0.72	$0.70	$0.51	$0.83	$0.62	$1.46	$0.87	$1.66	$1.76	$1.05
Adjusted Weighted Average Diluted Shares Outstanding	148.92M	149.30M	150M	152.22M	155.57M	157.60M	161.93M	164.12M	161.86M	160.77M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	148.67M	149.19M	149.53M	150.93M	152.25M	154.20M	156.32M	156.85M	158.17M	158.60M
Normalized Net Operating Profit after Tax (NOPAT)	103	107	82	95	126	131	224	259	252	187
Normalized NOPAT Margin	22.72%	21.38%	14.56%	14.83%	17.62%	17.67%	24.01%	23.42%	22.17%	16.14%
Pre Tax Income Margin	34.09%	29.55%	19.89%	19.59%	15.69%	37.43%	15.92%	27.26%	29.79%	16.02%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	100.44	85.23	16.17	13.32	6.13	15.37	11.59	27.58	30.89	12.59
NOPAT to Interest Expense	66.55	61.03	11.13	13.39	5.80	6.80	16.02	22.89	22.47	11.89
EBIT Less CapEx to Interest Expense	87.54	75.56	14.11	11.27	4.96	12.68	8.41	23.61	27.48	8.59
NOPAT Less CapEx to Interest Expense	53.65	51.36	9.07	11.33	4.63	4.11	12.85	18.92	19.06	7.90
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	43.72%	45.57%	62.20%	38.03%	50.34%	21.33%	35.55%	19.07%	17.62%	29.99%
Augmented Payout Ratio	43.72%	45.57%	62.20%	38.03%	66.38%	43.18%	66.48%	80.25%	24.47%	77.61%

This table displays calculated financial ratios and metrics derived from Bio-Techne's official financial filings.

Metric	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	4.63%	0.86%	1.30%	4.54%	2.70%	0.37%	3.16%	1.59%	4.52%	8.96%	4.20%
EBITDA Growth	-5.68%	8.17%	-7.45%	14.10%	-5.86%	-35.31%	-12.01%	-39.17%	-12.54%	14.33%	-29.72%
EBIT Growth	-10.92%	8.89%	-11.32%	17.32%	-12.00%	-50.82%	-16.47%	-51.52%	-18.94%	28.42%	-42.23%
NOPAT Growth	-24.72%	-1.97%	-11.21%	28.02%	17.97%	-38.83%	-23.38%	-44.74%	-41.81%	23.43%	-57.55%
Net Income Growth	30.09%	-30.61%	16.75%	21.92%	-43.17%	-45.08%	-30.13%	-46.23%	-34.11%	27.03%	-53.96%
EPS Growth	30.09%	-36.73%	16.22%	23.08%	-43.64%	-45.16%	-27.91%	-45.83%	-32.26%	29.41%	-54.84%
Operating Cash Flow Growth	15.79%	-36.25%	-30.90%	-18.81%	5.89%	29.09%	60.26%	-9.47%	7.59%	1.48%	-49.23%
Free Cash Flow Firm Growth	68.26%	58.17%	-74.46%	-1,063.31%	-661.01%	-442.42%	76.20%	79.73%	120.00%	122.81%	174.11%
Invested Capital Growth	6.00%	7.18%	21.05%	23.37%	25.86%	22.92%	5.90%	5.18%	-2.15%	-2.22%	-1.32%
Revenue Q/Q Growth	-6.44%	0.71%	8.31%	2.44%	-8.09%	-1.57%	11.31%	0.88%	-5.44%	2.62%	6.45%
EBITDA Q/Q Growth	-22.06%	14.03%	13.31%	13.31%	-35.69%	-21.65%	43.31%	-21.66%	-7.54%	2.42%	-5.26%
EBIT Q/Q Growth	-30.10%	20.55%	18.15%	17.85%	-47.57%	-32.63%	76.29%	-31.61%	-12.33%	6.73%	-9.72%
NOPAT Q/Q Growth	-22.79%	4.89%	37.42%	15.03%	-28.85%	-45.61%	72.12%	-17.03%	-25.08%	15.37%	-40.80%
Net Income Q/Q Growth	44.93%	-44.27%	40.42%	7.50%	-32.45%	-46.14%	78.62%	-17.27%	-17.22%	3.84%	-35.26%
EPS Q/Q Growth	44.93%	-43.64%	38.71%	11.63%	-35.42%	-45.16%	82.35%	-16.13%	-19.23%	4.76%	-36.36%
Operating Cash Flow Q/Q Growth	-45.40%	14.81%	-21.51%	65.02%	-28.79%	39.97%	-2.56%	-6.78%	-15.37%	32.02%	-51.25%
Free Cash Flow Firm Q/Q Growth	-263.44%	-31.82%	-314.03%	-7.99%	-29.12%	6.04%	81.83%	8.04%	227.38%	7.16%	-40.96%
Invested Capital Q/Q Growth	6.14%	0.56%	15.16%	0.38%	8.28%	-1.79%	-0.79%	-0.31%	0.74%	-1.86%	0.13%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	66.60%	67.52%	68.73%	67.93%	66.87%	64.78%	67.43%	66.43%	63.23%	65.27%	67.86%
EBITDA Margin	30.76%	34.83%	36.44%	40.31%	28.20%	22.45%	31.08%	24.14%	23.60%	23.55%	20.96%
Operating Margin	20.88%	25.00%	27.27%	31.37%	20.17%	13.94%	22.08%	14.97%	13.81%	15.96%	12.24%
EBIT Margin	20.88%	25.00%	27.27%	31.37%	17.90%	12.25%	22.08%	14.97%	13.88%	14.43%	12.24%
Profit (Net Income) Margin	33.28%	18.41%	23.87%	25.05%	18.41%	10.08%	16.17%	13.26%	11.61%	11.75%	7.14%
Tax Burden Percent	86.52%	75.28%	87.56%	85.47%	102.90%	82.26%	80.31%	97.43%	83.64%	81.37%	59.02%
Interest Burden Percent	184.16%	97.85%	99.98%	93.43%	100.00%	100.00%	91.17%	90.92%	100.00%	100.00%	98.88%
Effective Tax Rate	13.48%	24.72%	12.44%	14.53%	-2.90%	17.74%	19.69%	2.57%	16.36%	18.63%	40.98%
Return on Invested Capital (ROIC)	11.42%	11.91%	13.94%	15.91%	11.55%	6.44%	9.43%	7.79%	5.97%	6.98%	3.94%
ROIC Less NNEP Spread (ROIC-NNEP)	70.36%	-14.35%	13.93%	9.41%	7.97%	3.81%	7.25%	5.13%	6.05%	5.17%	3.81%
Return on Net Nonoperating Assets (RNNOA)	2.88%	-0.03%	0.95%	0.42%	0.77%	0.29%	0.81%	0.39%	0.58%	0.52%	0.38%
Return on Equity (ROE)	14.30%	11.88%	14.89%	16.33%	12.32%	6.73%	10.24%	8.18%	6.55%	7.50%	4.32%
Cash Return on Invested Capital (CROIC)	7.94%	6.81%	-6.83%	-7.77%	-10.31%	-8.83%	4.55%	3.58%	9.37%	9.91%	7.59%
Operating Return on Assets (OROA)	10.10%	11.99%	12.51%	14.46%	8.02%	5.51%	9.58%	6.50%	5.92%	6.39%	5.52%
Return on Assets (ROA)	16.10%	8.83%	10.95%	11.54%	8.25%	4.53%	7.01%	5.75%	4.95%	5.20%	3.22%
Return on Common Equity (ROCE)	14.27%	11.88%	14.90%	16.33%	12.32%	6.73%	10.24%	8.18%	6.55%	7.50%	4.32%
Return on Equity Simple (ROE_SIMPLE)	16.21%	14.33%	14.39%	0.00%	12.35%	11.42%	10.08%	0.00%	7.05%	7.61%	6.52%
Net Operating Profit after Tax (NOPAT)	49	51	70	81	57	31	54	45	33	39	23
NOPAT Margin	18.07%	18.82%	23.88%	26.81%	20.76%	11.47%	17.73%	14.58%	11.55%	12.99%	7.23%
Net Nonoperating Expense Percent (NNEP)	-58.94%	26.26%	0.01%	6.51%	3.58%	2.62%	2.18%	2.65%	-0.08%	1.81%	0.13%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	1.30%	-	-	-	1.62%	0.97%
Cost of Revenue to Revenue	33.40%	32.48%	31.27%	32.07%	33.13%	35.22%	32.57%	33.57%	36.77%	34.73%	32.14%
SG&A Expenses to Revenue	36.85%	34.25%	33.74%	28.79%	38.03%	42.43%	36.86%	43.63%	41.17%	40.89%	47.84%
R&D to Revenue	8.86%	8.27%	7.72%	7.77%	8.67%	8.41%	8.49%	7.84%	8.25%	8.42%	7.77%
Operating Expenses to Revenue	45.72%	42.52%	41.46%	36.56%	46.70%	50.84%	45.35%	51.46%	49.41%	49.31%	55.62%
Earnings before Interest and Taxes (EBIT)	56	68	80	95	50	33	67	46	40	43	39
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	83	95	107	121	78	61	94	74	68	70	66
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	6.30	7.07	6.13	6.50	5.36	6.19	5.48	5.45	5.93	5.51	4.59
Price to Tangible Book Value (P/TBV)	36.74	33.12	24.88	22.86	23.85	28.07	21.36	19.15	18.92	17.53	15.30
Price to Revenue (P/Rev)	9.87	11.53	10.32	11.24	9.37	10.61	9.57	9.73	10.82	9.57	7.67
Price to Earnings (P/E)	37.77	49.31	42.73	44.80	43.44	54.20	54.39	67.09	84.11	72.37	70.40
Dividend Yield	0.46%	0.00%	0.54%	0.49%	0.59%	0.42%	0.46%	0.45%	0.40%	0.44%	0.55%
Earnings Yield	2.65%	2.03%	2.34%	2.23%	2.30%	1.84%	1.84%	1.49%	1.19%	1.38%	1.42%
Enterprise Value to Invested Capital (EV/IC)	6.10	7.06	5.60	6.11	4.81	5.54	5.06	5.14	5.71	5.26	4.29
Enterprise Value to Revenue (EV/Rev)	9.93	11.53	10.51	11.37	9.62	10.88	9.78	9.87	10.92	9.67	7.82
Enterprise Value to EBITDA (EV/EBITDA)	28.27	32.30	30.19	28.50	27.01	32.89	30.84	36.94	42.63	37.46	33.45
Enterprise Value to EBIT (EV/EBIT)	38.31	43.74	41.44	37.32	36.89	46.40	44.19	57.77	67.77	58.36	55.01
Enterprise Value to NOPAT (EV/NOPAT)	45.58	53.13	50.21	51.31	42.54	52.05	50.58	61.17	78.41	67.87	68.09
Enterprise Value to Operating Cash Flow (EV/OCF)	33.34	43.58	43.15	50.82	42.73	45.08	36.78	38.28	42.14	37.96	35.71
Enterprise Value to Free Cash Flow (EV/FCFF)	79.02	107.27	0.00	0.00	0.00	0.00	114.24	147.48	60.24	52.49	56.19
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.16	0.11	0.20	0.18	0.22	0.23	0.19	0.15	0.14	0.14	0.16
Long-Term Debt to Equity	0.15	0.11	0.20	0.18	0.22	0.23	0.19	0.15	0.14	0.14	0.16
Financial Leverage	0.04	0.00	0.07	0.04	0.10	0.08	0.11	0.08	0.10	0.10	0.10
Leverage Ratio	1.36	1.32	1.36	1.35	1.36	1.34	1.36	1.32	1.33	1.34	1.33
Compound Leverage Factor	2.50	1.29	1.36	1.26	1.36	1.34	1.24	1.20	1.33	1.34	1.32
Debt to Total Capital	13.45%	9.87%	16.57%	15.24%	18.11%	18.54%	16.19%	13.36%	12.30%	12.61%	14.05%
Short-Term Debt to Total Capital	0.37%	0.00%	0.23%	0.15%	0.07%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	13.08%	9.87%	16.34%	15.09%	18.04%	18.54%	16.19%	13.36%	12.30%	12.61%	14.05%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	86.55%	90.13%	83.43%	84.76%	81.89%	81.46%	83.81%	86.64%	87.70%	87.39%	85.95%
Debt to EBITDA	0.69	0.50	0.96	0.78	1.08	1.18	1.06	1.03	1.00	0.97	1.17
Net Debt to EBITDA	0.18	0.01	0.56	0.33	0.72	0.82	0.67	0.54	0.37	0.40	0.67
Long-Term Debt to EBITDA	0.67	0.50	0.95	0.77	1.08	1.18	1.06	1.03	1.00	0.97	1.17
Debt to NOPAT	1.12	0.82	1.60	1.40	1.71	1.87	1.74	1.70	1.84	1.76	2.38
Net Debt to NOPAT	0.28	0.01	0.93	0.59	1.13	1.30	1.09	0.89	0.69	0.72	1.36
Long-Term Debt to NOPAT	1.09	0.82	1.57	1.39	1.70	1.87	1.74	1.70	1.84	1.76	2.38
Altman Z-Score	12.50	15.95	11.20	12.88	9.84	10.81	10.75	12.03	14.12	12.99	10.23
Noncontrolling Interest Sharing Ratio	0.22%	-0.01%	-0.03%	-0.02%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	4.01	4.40	4.04	4.84	4.63	4.37	4.08	3.87	4.56	3.94	3.71
Quick Ratio	2.74	2.97	2.65	3.29	2.76	2.54	2.49	2.47	2.89	2.45	2.23
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-54	-72	-296	-320	-413	-388	-71	-65	83	89	52
Operating Cash Flow to CapEx	586.87%	1,053.92%	430.16%	769.95%	436.90%	559.18%	492.59%	419.89%	696.57%	1,236.56%	406.20%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.48	0.48	0.46	0.46	0.45	0.45	0.43	0.43	0.43	0.44	0.45
Accounts Receivable Turnover	6.95	6.63	5.37	5.50	6.04	5.84	5.20	5.04	5.47	5.62	5.20
Inventory Turnover	2.64	2.52	2.41	2.35	2.19	2.21	2.20	2.22	2.18	2.23	2.23
Fixed Asset Turnover	5.18	5.14	5.08	5.06	5.02	5.00	4.94	4.86	4.83	4.94	4.88
Accounts Payable Turnover	12.57	13.96	12.35	12.32	12.59	13.53	13.68	12.23	13.55	12.72	13.68
Days Sales Outstanding (DSO)	52.54	55.03	67.98	66.31	60.42	62.51	70.25	72.41	66.71	64.91	70.21
Days Inventory Outstanding (DIO)	138.45	144.99	151.72	155.58	166.42	165.39	166.19	164.70	167.63	163.88	163.37
Days Payable Outstanding (DPO)	29.05	26.14	29.54	29.62	29.00	26.97	26.68	29.83	26.94	28.69	26.69
Cash Conversion Cycle (CCC)	161.94	173.88	190.15	192.27	197.84	200.94	209.76	207.28	207.40	200.10	206.89
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	1,820	1,830	2,108	2,116	2,291	2,250	2,232	2,225	2,242	2,200	2,203
Invested Capital Turnover	0.63	0.63	0.58	0.59	0.56	0.56	0.53	0.53	0.52	0.54	0.55
Increase / (Decrease) in Invested Capital	103	123	367	401	471	420	124	110	-49	-50	-29
Enterprise Value (EV)	11,099	12,914	11,810	12,929	11,010	12,462	11,285	11,445	12,789	11,567	9,458
Market Capitalization	11,030	12,911	11,592	12,780	10,717	12,150	11,042	11,279	12,677	11,445	9,269
Book Value per Share	$44.66	$46.56	$12.02	$12.49	$12.63	$12.42	$12.81	$13.13	$13.48	$13.08	$12.77
Tangible Book Value per Share	$7.66	$9.93	$2.96	$3.55	$2.84	$2.74	$3.29	$3.74	$4.22	$4.11	$3.83
Total Capital	2,023	2,027	2,265	2,320	2,439	2,411	2,403	2,388	2,439	2,378	2,348
Total Debt	272	200	375	354	442	447	389	319	300	300	330
Total Long-Term Debt	265	200	370	350	440	447	389	319	300	300	330
Net Debt	69	3.24	218	149	293	311	244	166	112	122	189
Capital Expenditures (CapEx)	9.56	6.11	12	11	14	15	16	18	9.17	6.82	10
Debt-free, Cash-free Net Working Capital (DFCFNWC)	219	240	278	292	317	320	316	305	319	296	317
Debt-free Net Working Capital (DFNWC)	422	437	435	496	465	455	461	458	506	473	458
Net Working Capital (NWC)	414	437	430	493	464	455	461	458	506	473	458
Net Nonoperating Expense (NNE)	-41	1.10	0.01	5.31	6.49	3.80	4.75	4.05	-0.15	3.70	0.26
Net Nonoperating Obligations (NNO)	69	3.24	218	149	293	286	218	156	103	121	185
Total Depreciation and Amortization (D&A)	27	27	27	27	29	28	27	28	28	27	28
Debt-free, Cash-free Net Working Capital to Revenue	19.57%	21.43%	24.73%	25.70%	27.69%	27.93%	27.33%	26.33%	27.22%	24.74%	26.26%
Debt-free Net Working Capital to Revenue	37.74%	39.00%	38.72%	43.68%	40.69%	39.77%	39.92%	39.52%	43.23%	39.58%	37.89%
Net Working Capital to Revenue	37.08%	39.00%	38.25%	43.37%	40.54%	39.77%	39.92%	39.52%	43.23%	39.58%	37.89%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.57	$0.32	$0.45	$0.48	$0.32	$0.17	$0.31	$0.26	$0.21	$0.22	$0.14
Adjusted Weighted Average Basic Shares Outstanding	156.93M	157.01M	157.31M	157.18M	158.13M	157.53M	157.31M	157.71M	158.53M	158.43M	157.37M
Adjusted Diluted Earnings per Share	$0.55	$0.31	$0.43	$0.48	$0.31	$0.17	$0.31	$0.26	$0.21	$0.22	$0.14
Adjusted Weighted Average Diluted Shares Outstanding	162.17M	161.75M	161.62M	161.86M	161.94M	160.06M	160.50M	160.77M	161.12M	160.63M	158.94M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.48	$0.00	$0.00	$0.00	$0.26	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	156.97M	157.28M	157.44M	158.17M	158.15M	157.19M	157.58M	158.60M	158.89M	158.09M	156.77M
Normalized Net Operating Profit after Tax (NOPAT)	49	51	70	81	39	31	54	45	33	39	23
Normalized NOPAT Margin	18.07%	18.82%	23.88%	26.81%	14.12%	11.47%	17.73%	14.58%	11.55%	12.99%	7.23%
Pre Tax Income Margin	38.46%	24.46%	27.26%	29.31%	17.90%	12.25%	20.13%	13.61%	13.88%	14.43%	12.11%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	17.70%	19.18%	18.47%	17.62%	20.43%	22.48%	24.82%	29.99%	33.48%	32.02%	38.45%
Augmented Payout Ratio	81.29%	72.36%	47.30%	24.47%	20.43%	58.19%	64.25%	77.61%	33.48%	79.84%	171.88%

Frequently Asked Questions About Bio-Techne's Financials

When does Bio-Techne's fiscal year end?

According to the most recent income statement we have on file, Bio-Techne's financial year ends in June. Their financial year 2024 ended on June 30, 2024.

How has Bio-Techne's net income changed over the last 9 years?

Bio-Techne's net income appears to be on an upward trend, with a most recent value of $168.11 million in 2024, rising from $107.74 million in 2015. The previous period was $285.44 million in 2023. See Bio-Techne's forecast for analyst expectations on what’s next for the company.

What is Bio-Techne's operating income?

Bio-Techne's total operating income in 2024 was $206.69 million, based on the following breakdown:

Total Gross Profit: $769.73 million
Total Operating Expenses: $563.04 million

How has Bio-Techne revenue changed over the last 9 years?

Over the last 9 years, Bio-Techne's total revenue changed from $452.25 million in 2015 to $1.16 billion in 2024, a change of 156.3%.

How much debt does Bio-Techne have?

Bio-Techne's total liabilities were at $635.02 million at the end of 2024, a 5.5% decrease from 2023, and a 193.4% increase since 2015.

How much cash does Bio-Techne have?

In the past 9 years, Bio-Techne's cash and equivalents has ranged from $54.53 million in 2015 to $199.09 million in 2021, and is currently $151.79 million as of their latest financial filing in 2024.

How has Bio-Techne's book value per share changed over the last 9 years?

Over the last 9 years, Bio-Techne's book value per share changed from 22.80 in 2015 to 13.13 in 2024, a change of -42.4%.

Related Companies

This page (NASDAQ:TECH) was last updated on 6/12/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bio-Techne (TECH) Financials

Frequently Asked Questions About Bio-Techne's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bio-Techne (TECH) Financials

Annual Income Statements for Bio-Techne

Quarterly Income Statements for Bio-Techne

Annual Cash Flow Statements for Bio-Techne

Quarterly Cash Flow Statements for Bio-Techne

Annual Balance Sheets for Bio-Techne

Quarterly Balance Sheets for Bio-Techne

Annual Metrics And Ratios for Bio-Techne

Quarterly Metrics And Ratios for Bio-Techne

Frequently Asked Questions About Bio-Techne's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools